TAMPA, Fla., April 21, 2016 /PRNewswire/ -- Point Guard Biosciences, LLC (PGBio) is pleased to announce the winner of the inaugural PGBio Innovation in Ophthalmology Award. This award was created by PGBio to assist entrepreneurs in the area of ophthalmology with financial help as well as assistance with strategic planning.
The award recipient was chosen based on novelty of the medical research, and the ability of the project to improve the quality of life of patients. The winner will be awarded a cash prize of $10,000. In addition to the cash prize, the award recipient will receive assistance by the PGBio team with the development of a business plan.
Judges for the award included Gary D. Novack, Ph.D.,president of PharmaLogic Development, Inc. and Visiting Professor, University of California, Davis, School of Medicine., Pierre-Paul Elena, Chairman and Chief Scientific Officer of Iris Pharma, Ali Behbahani, MD, Partner at NEA, and Barry Butler, Managing Partner of Point Guard Partners and CEO of Point Guard Biosciences.
The winner of the 2016 award is Dr. Giulio Ferrari from San Raffaele Hospital, Milan, Italy for his work related to the use of neurokinin 1 receptor (NK1-R) antagonists to treat corneal neovascularization. Corneal neovascularization is a condition that occurs when unwanted blood vessels grow across the cornea, leading to visual impairment and corneal scarring. It can be caused by extended wear contact lenses and by a number of different ophthalmic diseases. Corneal neovascularization is a major factor in corneal graft rejection and is a leading cause of vision loss in the world.
"We were very pleased with the reception to this award in the ophthalmic community. We received 31 application packages from all over the world covering technologies addressing unmet medical needs across the spectrum of ophthalmology" said Barry Butler, CEO of Point Guard Biosciences. "It was a very difficult decision for the judges and there were several packages deserving of the prize. We congratulate Dr. Ferrari for being chosen from such a strong field of applicants."
About Point Guard Biosciences
Point Guard Biosciences is devoted to finding, funding and developing innovative technologies in the areas of ophthalmic pharmaceuticals and medical devices. The staff of PGBio has extensive experience developing ophthalmic products, raising venture capital, and managing start-up companies. To learn more about Point Guard Bioscience, please visit our website: www.pointguard.bio
PGBio is a member of the Point Guard Partners (PGP) family of companies. Other companies in the PGP family include Oculos Clinical Research, a full service ophthalmology-focused CRO and Oculos Consulting, which provides regulatory affairs and CMC consulting services to ophthalmic companies.
To learn more about all the companies in the PGP family, please visit our website: www.pointguardllc.com
Contact: Rosa Corrales, Ph. D
SOURCE Point Guard Biosciences, LLC